Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

Pozen Looking Very Attractive As FDA Decision Nears

On March 5, 2014, Pozen, Inc. (NASDAQ:POZN) reported financial results for the fourth quarter and full year ended December 31, 2013. Total revenues in the fourth quarter were $4.7 million, comprised of $1.7 million in royalties on roughly $25 million in sales of Vimovo at AstraZeneca (NYSE:AZN) and $3.0 million in licensing revenue relating to amortization of the $15 million upfront payment from Sanofi U.S. on the PA licensing agreement in September 2013. Revenues for the fourth quarter were essentially dead-on with our forecast. Revenues for the full year 2013 totaled approximately $10.3 million, which included $6.3 million in royalties from roughly $91 million in worldwide sales of Vimovo at AstraZeneca and $4.0 million in amortized...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details